Genocea Biosciences Inc (NASDAQ:GNCA) shares fell 5.1% on Friday . The company traded as low as $0.90 and last traded at $0.93. 1,768,341 shares changed hands during trading, an increase of 36% from the average session volume of 1,300,616 shares. The stock had previously closed at $0.98.

A number of research firms recently weighed in on GNCA. Needham & Company LLC raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research report on Tuesday, February 6th. Zacks Investment Research downgraded shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $5.00 price objective on shares of Genocea Biosciences in a report on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. Genocea Biosciences currently has a consensus rating of “Hold” and a consensus target price of $4.45.

The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of 2.51.

A number of hedge funds and other institutional investors have recently bought and sold shares of GNCA. GSA Capital Partners LLP purchased a new stake in Genocea Biosciences during the second quarter worth about $100,000. Ameriprise Financial Inc. increased its stake in shares of Genocea Biosciences by 11.5% in the second quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 2,300 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Genocea Biosciences in the second quarter worth about $157,000. New York State Common Retirement Fund purchased a new position in shares of Genocea Biosciences in the second quarter worth about $159,000. Finally, OxFORD Asset Management LLP purchased a new position in shares of Genocea Biosciences in the second quarter worth about $204,000. Institutional investors and hedge funds own 12.02% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Genocea Biosciences (GNCA) Stock Price Down 5.1%” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://theolympiareport.com/2018/02/11/genocea-biosciences-gnca-stock-price-down-5-1.html.

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.